1. Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma Gartrell, Robyn D.; Marks, Douglas K.; Rizk, Emanuelle M.; Bogardus, Margaret Haskell; Gérard, Camille L.; Barker, Luke William; Fu, Yichun; Esancy, Camden L.; Li, Gen; Ji, Jiayi; Rui, Shumin; Ernstoff, Marc S.; Taback, Bret; Pabla, Sarabjot; Chang, Rui; Lee, Sandra J.; Krolewski, John J.; Morrison, Carl; Horst, Basil; Saenger, Yvonne M. 2019 Articles MelanomaMelanoma--Immunological aspectsMelanoma--Genetic aspectsBiometryMedicine
2. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma Clark, Joseph I.; Singh, Jatinder; Ernstoff, Marc S.; Lao, Christopher D.; Flaherty, Lawrence E.; Logan, Theodore F.; Curti, Brendan; Agarwala, Sanjiv S.; Taback, Bret; Cranmer, Lee; Lutzky, Jose; Luna, Theresa L.; Aung, Sandra; Lawson, David H. 2018 Articles Cancer--ImmunotherapyInterleukin-2Melanoma--TreatmentEnzyme inhibitors
3. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition Blake, Zoë; Marks, Douglas K.; Gartrell, Robyn D.; Hart, Thomas; Horton, Patti; Cheng, Simon K.; Taback, Bret; Horst, Basil; Saenger, Yvonne M. 2018 Articles Cancer--ImmunotherapyMelanoma--TreatmentMetastasisCancer--Treatment--Research
4. Quantitative Analysis of Immune Infiltrates in Primary Melanoma. Gartrell, Robyn D.; Marks, Douglas K.; Hart, Thomas D.; Li, Gen; Davari, Danielle R.; Wu, Alan; Blake, Zoë; Lu, Yan; Askin. Kayleigh N.; Monod, Anthea; Esancy, Camden L.; Stack, Edward C.; Jia, Dan Tong; Armenta, Paul M.; Fu, Yichun; Izaki, Daisuke; Taback, Bret; Rabadan, Raul; Kaufman, Howard L.; Drake, Charles G.; Horst, Basil; Saenger, Yvonne M. 2018 Articles MelanomaMelanoma--HistopathologyMelanoma--Immunological aspectsTumors--Immunological aspectsImmunofluorescenceMachine learning
5. A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01) Clark, Joseph; Flaherty, Lawrence; Ernstoff, Marc; Koon, Henry; Milhem, Mohammed; Militello, Gerald; Agarwala, Sanjiv; Curti, Brendan; Cranmer, Lee; Lao, Christopher; Logan, Theodore; Lutzky, Jose; Rudrapatna, Venkatesh; Daniels, Gregory; Taback, Bret; Aung, Sandra; Lowder, James; Lawson, David 2014 Articles Melanoma--TreatmentMetastasisOncology
6. Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02) Patel, Sapna; Milhem, Mohammed; Hallmeyer, Sigrun; Daniels, Gregory; Cranmer, Lee; Taback, Bret; Flaherty, Lawrence; Aung, Sandra; Lowder, James; Sharfman, William 2014 Articles MetastasisMelanoma--TreatmentOncology
7. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma Kaufman, Howard; Taback, Bret; Sherman, William; Kim, Dae; Shingler, William; Moroziewicz, Dorota; DeRaffele, Gail; Mitcham, Josephine; Carroll, Miles; Harrop, Richard; Naylor, Stuart; Kim-Schulze, Seunghee 2009 Articles Oncology